This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Puma Biotech Gets FDA Nod of Labeling Supplement for Nerlynx
by Zacks Equity Research
The FDA approves the label update of Puma Biotech's (PBYI) breast cancer drug Nerlynx in order to add data from the CONTROL study. Stock gains.
Incyte Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Incyte has been struggling lately, but the selling pressure may be coming to an end soon.
Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down
by Zacks Equity Research
Bausch's (BHC) shares down on lawsuit filed against Novartis' Sandoz defending Xifaxan patents.
Merck's Pediatric Filings for Dificid Get FDA's Priority Review
by Zacks Equity Research
The FDA accepts and grants a priority review to Merck's (MRK) two filings for pediatric approvals of antibacterial medicine Dificid for Clostridium infections. The verdict will be out on Jan 24, 2020.
Is Incyte (INCY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (INCY) Outperforming Other Medical Stocks This Year?
Incyte (INCY) Stock Up 16% YTD on Strong Jakafi Performance
by Zacks Equity Research
Incyte (INCY) outperforms the industry on strong performance of Jakafi and encouraging pipeline progress.
Incyte Treats First Patient in Phase III Vitiligo Study
by Zacks Equity Research
Incyte (INCY) treats first patient in the TRuE-V clinical program on the cream formulation of ruxolitinib for the treatment of vitiligo.
Merck's Keytruda Combo Gets FDA Nod for Endometrial Carcinoma
by Zacks Equity Research
Merck (MRK) receives accelerated approval for label expansion of Keytruda in combination with Lenvima for treating certain types of endometrial carcinoma. Its Ebola vaccine BLA gets priority review.
Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA
by Zacks Equity Research
The FDA grants a Breakthrough Therapy status to Novartis' (NVS) capmatinib for the first-line treatment of patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer.
Merck's Keytruda Combination Gets EC Nod for Kidney Cancer
by Zacks Equity Research
Merck's (MRK) label expansion application for Keytruda in combination with Pfizer's Inlyta for the first-line treatment of renal cell carcinoma gets approval in Europe.
Why Is Incyte (INCY) Down 4.2% Since Last Earnings Report?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study
by Zacks Equity Research
Lilly (LLY) is conducting five studies on Olumiant (baricitinib) under the atopic dermatitis (AD) program and BREEZE-AD7 is the third study to be completed this year.
Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer
by Zacks Equity Research
Celgene's (CELG) oncology portfolio gets a boost with the FDA approval of Inrebic for rare bone marrow cancer.
Incyte (INCY) Q2 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Incyte (INCY) reports better-than-expected results for the second quarter of 2019, owing to strong Jakafi sales.
Incyte (INCY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of 53.06% and 5.79%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on top- and bottom-line numbers along with other pipeline updates, when Zoetis reports Q2 results.
Exelixis (EXEL) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Exelixis' (EXEL) second-quarter 2019 results are expected to benefit from increase in Cabometyx sales. Investors will focus on other pipeline updates as well.
Will Strong HIV Sales Drive Gilead's (GILD) Q2 Earnings?
by Zacks Equity Research
Investors are expected to focus on the HIV franchise's performance and other pipeline updates, when Gilead (GILD) reports second-quarter 2019 results.
Will Strong Jakafi Sales Drive Incyte (INCY) Q2 Earnings?
by Zacks Equity Research
Investors will primarily focus on Jakafi sales and pipeline updates, when Incyte (INCY) reports second-quarter 2019 results.
5 Drug/Biotech Stocks Set to Beat Earnings Estimates in Q2
by Zacks Equity Research
We take a look at the overall drug/biotech sector's performance and five stocks that are poised to beat on earnings in the second quarter of 2019.
Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Merck's Keytruda sBLAs for 6-Week Dosing to be Reviewed by FDA
by Zacks Equity Research
FDA accepts Merck's (MRK) sBLAs for a six-week dosing schedule of Keytruda for melanoma and multiple other indications
Incyte Out-Licenses INCMGA0012 Rights in China to Zai Lab
by Zacks Equity Research
Incyte (INCY) inks a licensing deal with Zai Lab to develop and commercialize INCMGA0012 for hematology and oncology indications in Greater China.